Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN) in Male: Presentation, Outcome & Poor Prognostic Factors
DOI:
https://doi.org/10.14738/bjhr.1203.18760Keywords:
Systemic lupus erythematous, Lupus Nephritis, Chronic Kidney diseaseAbstract
Introduction: Systemic lupus erythematosus (SLE) is common in female, while lupus nephritis (LN) is more common in male. Methods: we analyze clinical & lab parameters of male SLE patients since 2009, also reported incidence, histopathological classes & outcome of LN. Results: Total 61 male patients were diagnosed with SLE. Antinuclear antibody (ANA), Ant Ds DNA antibody (ds DNA Ab) & Lupus anticoagulant (LA) were positive in 75.40%, 67.21% & 40.98% of patients respectively, also Low C3 & C4 were observed in 57.09% & 34.70% respectively. Incidence of LN was 54.09%. Constitutional manifestations were most common presenting complain in both LN & rest of the SLE patients (RoSLE) (LN vs RoSLE: 48.48% vs 57.14% p-value: >0.05). Regarding lab parameters, RoSLE patients show more positive ANA (LN vs RoSLE: 69.69% vs 82.14%, p=>0.05), ds DNA Ab (LN vs RoSLE: 60.60% vs 75%, p=>0.05) & LA (LN vs RoSLE: 33.33% vs 50%, p=>0.05) titer. Mean creatinine (Cr) was 0.90±0.70 mg/dl in LN & 0.81±0.23 (p=>0.05) in the RoSLE patients. also decrease serum Albumin (Alb) was observed in LN patients (LN vs RoSLE: 2.85±1.85 vs 4.25±0.82, p=<0.05). Class IV was most common lesion in 48.48%, also 24.24% LN patients reached to chronic kidney disease stage V. CKD V-LN patients were older (CKD vs CKD-V: 37.68±12.18 vs 43±10.75, p=<0.05) & have positive ANA (37.5%), ds DNA ab (37.5%) & LA (25%) titer, also low C3 were more common in CKD-V patients than low C4 [CKD other stages vs CKD-V: (Low C3; 44% vs 62.5%, p>0.05) & (Low C4; 32% vs 25%, p>0.05). Median Cr & Alb was 0.9(0.52) & 2.6(1.7) in other stages of CKD, while 2.8(4.9) & 3.17(1.27) in CKD-V patients. Mean duration from diagnosis of LN to attend CKD-V was 13.34±7.50 years. Conclusion: More than half of SLE patients had LN, with class IV is most common histopathological lesion. Incidence of CKD-V in LN was significantly high, belongs to older age group and have minimal extra-renal manifestations, that probably explains late presentation & relatively poor renal outcome, however there was no statistical significant risk factor between LN & the RoSLE.
References
Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Review: Male systemic lupus erythematosus: A review of sex disparities in this disease. Lupus 2010; 19:119-29.
Agrawaal KK, Dhakal SS. Systemic lupus erythematosus in males: A case series. Saudi J Kidney Dis Transpl 2014;25:638-42.
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.
Relle M, Foehr B, Schwarting A. Epigenetic aspects of systemic lupus erythematosus. Rheumatol Ther. 2015;2:33–46.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400-12.
Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: Strengths, weaknesses, and opportunities for improvement. Lupus 1999;8:586-95
Seligman VA, Lum RF, Olson JL, Hongzhe Li, Criswell LA. Demographic differences in the development of lupus nephritis: A retrospective analysis. Am J Med 2002;15;112:726-9. 395
LM Ortega, DR Schultz, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: Pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010;19:557-74.
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
Lohita RG. Gender disparity in systemic lupus erythematosus, thoughts after the 8th International Congress on Systemic Lupus Erythematosus, Shanghai, Chaina, 2007. J Clin Rheumatol 2008;14:185-7.
Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008;17:412-5.
Robert W, McMurray, May W. Sex hormones and systemic lupus erythematosus: Review and meta-analysis. Arthritis Rheum 2003;48:2100-10.
Grimaldi CM, Hill L, Xu X, Peeva E, Diamond B. Hormonal modulation of B cell development and repertoire selection. Mol Immunol 2005;42:811-20.
Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwait AB. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006;312:1669-72.
Santiago-Raber ML, Kikuchi S, Borel P, Uematsu S, Akira S, Kotzin BL, Izui S. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol. 2008 Jul 15;181(2):1556-62.
Shen N, Fu Q, Deng Y, Qian X, Zhao J, Kaufman KM, et al. Sex-specific association of X-linked Toll-like receptor 7(TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 2010;107:15838-43.
Gandolfo MT, Verzola D, Salvatore F, Gianiorio G, Procopio V, Romagnoli A, et al. Gender and the progression of chronic renal diseases: Does apoptosis make the difference? Minerva Urol Nefrol 2004;56:1-14.
AlSaleh J, Jassim V, ElSayed M, Saleh N, Harb D. Clinical and immunological manifestations in 151 SLE patients living in Dubai. Lupus 2008;17:62-6.)
Adwan M. Clinical and serologic characteristics of systemic lupus erythematosus in the arab world: A pooled analysis of 3,273 patients. Arch Rheumatol 2018;33(4):455-463.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-24.
Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 2004;83:1-17.
Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009;18:465-73.
Abutiban F, Mokkaddam K, Ameen E, Moussa M, Alsaeid K. Comparison between familial and sporadic systemic lupus erythematosus in Kuwaiti patients. Lupus 2009;18:86-91.
Al-Maini MH, El-Ageb EM, Al-Wahaibi SS, Al-Farsi Y, Richens ER. Demographic, autoimmune, and clinical profiles of patients with systemic lupus erythematosus in Oman. Rheumatol Int 2003;23:186-91.
Font J, Cervera R, Ramos-Casals M, García-Carrasco M, Sents J, Herrero C, et al. Clusters of clinical and immunologic features in systemic lupus erythematosus: Analysis of 600 patients from a single center. Semin Arthritis Rheum 2004;33:217-30.
Cerevera R, Khamasta MA, Font J, Sebastimani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestation in acohort of 1000 patients. Medicine (Baltimore) 2003;82:299-308.
K. M. Wissing, D. Abramowicz, N. Broeders, and P. Vereerstraeten, “Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection,” Transplantation, vol. 70, no. 3, pp. 464–472, 2000 396
Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol 2016;68:1432–41
M. A. Garcia, J. C. Marcos, A. I. Marcos et al., “Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients,” Lupus, vol. 14, no. 12, pp. 938–946, 2005. [13] SS. Stefanidou, A. Benos, V. Galanopoulou et al., “Clinical expression and morbidity of systemic lupus erythematosus during a postdiagnostic 5-year follow-up: a male:female comparison,” Lupus, vol. 20, no. 10, pp. 1090–1094, 2011.
Basu MBK, De S, Karmakar S, Sengupta M, Sircar D, Roychowdhury A, et al. Native renal biopsy: An essential diagnostic tool in systemic lupus erythematosus. Ann Pathol Lab Med 2018;5:647-52.
de Carvalho JF, do Nascimento AP, Testagrossa LA, Barros RT, Bonfá E. Male gender results in more severe lupus nephritis. Rheumatol Int 2010;30:1311-5.
(Wang YF, Xu YX, Y Tan, F Yu, M-H Zhao. Clinicopathological characteristics and t J, Yang F, Sui D, Guo Q, Dong C, Wang J, et al. Clinical and pathological characteristics of male patients with systemic lupus erythematosus from northeast China: A ten-year retrospective study. Int J Clin Exp Pathol 2017;10:6082-91.
Patel M, Clarke AM, Bruce IN, Symmons DPM. The prevalence and incidence of biopsy-proven lupus nephritis in the UK. Arthritis Rheum 2006;54:2963-9.
Medina G, Vera Lastra O, Barile L Salas M, Jara LJ. Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: A comparative study of 73 patients. Lupus 2004;13:11-6.
Liu J, Yang F, Sui D, Guo Q, Dong C, Wang J, et al. Clinical and pathological characteristics of male patients with systemic lupus erythematosus from northeast China: A ten-year retrospective study. Int J Clin Exp Pathol 2017;10:6082-91.
T. C. Tan, H. Fang, L. S. Magder, and M. A. Petri, “Differences between Male and Female Systemic Lupus Erythematosus in a Multiethnic Population,” The Journal of Rheumatology, vol. 39, no. 4, pp. 759–769, 2012.
M. A. Garcia, J. C. Marcos, A. I. Marcos et al., “Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients,” Lupus, vol. 14, no. 12, pp. 938–946, 2005.
J. F. Molina, C. Drenkard, J. Molina et al., “Systemic lupus erythematosus in males: a study of 107 Latin American patients,” Medicine, vol. 75, no. 3, pp. 124–130, 1996.
S. Stefanidou, A. Benos, V. Galanopoulou et al., “Clinical expression and morbidity of systemic lupus erythematosus during a post-diagnostic 5-year follow-up: a male:female comparison,” Lupus, vol. 20, no. 10, pp. 1090–1094, 2011.
Hsu CY, Chiu WC, Yang TS, Chen CJ, Chen YC, Lai HM, et al. Age-and gender related long term renal outcome in patients with lupus nephritis. Lupus 2011;20:1135-41.
Urrestarazú A, Otatti G, Silvariño R, Garau M, Coitiño R, Alvarez A, et al. Lupus nephritis in males: Clinical features, course, and prognostic factors for end-stage renal disease. Kidney Int Rep 2017;2:905-12.
Vandepapelière J, Aydin S, Cosyns J-P, et al. Prognosis of proliferative lupus nephritis subsets in the Louvain lupus nephritis inception cohort. Lupus2014;23:159 65.doi:10.1177/0961203313514623.
Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol2016;68:1432–41.doi:10.1002/art.39594.
Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci 2013;346:319-23.
Tselios K, Gladman DD, Taheri C, Su J, Urowitz MB. Factors Associated with Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. J Rheumatol. 2021 Feb;48(2):228-231. doi: 10.3899/jrheum.200161. Epub 2020 Sep 1. PMID: 33259331.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kashif Gulzar, Dileep Kumar, Fakhriya J Alawi, Sima Najad, Maseer Ahmed, Aisha Bibi, Faraz Khan, Faisal Elbadaw, Amna Al Hadari
This work is licensed under a Creative Commons Attribution 4.0 International License.
